Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
34784798
DOI
10.2217/imt-2021-0069
Knihovny.cz E-zdroje
- Klíčová slova
- CD8+ T lymphocytes, breast cancer, cellular immunity, immune rehabilitation, immunomodulation, pleuran, β-glucan,
- MeSH
- beta-glukany imunologie MeSH
- imunomodulace imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prsu imunologie MeSH
- Pleurotus imunologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- beta-glukany MeSH
Aim: To evaluate the effect of pleuran (β-glucan from Pleurotus ostreatus) administration on the immune profile of patients with endocrine-dependent breast cancer (clinical stages I-II) in clinical and imaging remission. Methodology: Antitumor cellular immunity (CD19+, CD3+, CD4+ and CD8+ T lymphocytes and natural killer cells) of 195 patients (49 in the pleuran group and 146 in the control group) was measured by flow cytometry. Results: We observed a significant increase in the absolute number of CD3+, CD19+, CD4+ and CD8+ T lymphocytes in the pleuran group compared with the control group. Conclusion: Our results suggest potential benefit of continuous pleuran administration on immune rehabilitation of cellular antitumor immunity and better prognosis in breast cancer patients in remission.
Lay abstract We aimed to evaluate the effect of pleuran (β-glucan from oyster mushroom) on the selected immune parameters of patients with breast cancer in remission. We studied antitumor cellular immune parameters of 195 patients (49 in the pleuran group and 146 in the control group) by means of flow cytometry. After 12 months, we measured a significant increase of cytotoxic T lymphocytes in the pleuran group compared with a significant decrease in the control group. Our results suggest potential benefit of long-term administration of pleuran on antitumor cellular immunity and better prognosis in breast cancer patients in remission.
Citace poskytuje Crossref.org